Fundz

Ellipses Pharma Limited Launches Groundbreaking Clinical Trial Programme in the United Arab Emirates for Cancer Treatment.

Dec 23, 2024
United Arab EmiratesBiotechnologyHealth CareMedicalTherapeuticsPharmaceutical

Product Description

Ellipses Pharma Limited has initiated a large-scale Phase 1/2 oncology clinical study in the United Arab Emirates, focusing on its next generation selective RET inhibitor, EP0031/A400, aimed at treating RET-altered tumours prevalent in non-small cell lung and thyroid cancers.

Company Information

Company

Ellipses Pharma Limited

Location

United Arab Emirates

About

Ellipses Pharma Limited is a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model. The company aims to find outstanding potential cancer treatments and develop them swiftly, supported by a strong investor base. Ellipses specializes in next generation selective RET inhibitors for treating RET-altered tumors, particularly in non-small cell lung and thyroid cancers. Its mission includes bringing hope and innovative therapies to patients, especially in the Middle East.

Fundz sees it the moment Ellipses Pharma Limited ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

David hidden

hidden

Ascanio hidden

hidden

Luke hidden

hidden

Eden hidden

hidden

Suzanne hidden

hidden
Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Ellipses Pharma Limited's next move

Learn about Strategic plan

Product Launch Insights

What this usually means
Market expansion signals
New product launches often coincide with market expansion initiatives

Ellipses Pharma Limited shipped something new. Fundz reads product launches, trademark filings and hiring together.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.